1 In The Lancet Infectious Diseases, Katia Alves and colleagues 5 report the interim analysis of the immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback